• Je něco špatně v tomto záznamu ?

Bladder sparing landscape for bacillus Calmette-Guérin unresponsive bladder cancer

F. Soria, A. Giordano, SF. Shariat, P. Gontero,

. 2020 ; 30 (4) : 542-546. [pub] -

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články, přehledy

Perzistentní odkaz   https://www.medvik.cz/link/bmc20028042

PURPOSE OF REVIEW: The treatment of bacillus Calmette-Guérin (BCG) unresponsive disease remains a challenge for urooncologists. The search for effective conservative treatments is ongoing and several new agents have been recently tested for this purpose. The aim of this manuscript was to review the last developments in this interesting field. RECENT FINDINGS: The advent of systemic immunotherapy in the nonmuscle invasive setting promise to revolutionize the paradigm of treatment of BCG unresponsive disease. The preliminary results of the Keynote-057 trial (3 months complete response of 41% in carcinoma-in-situ patients) have led to the rapid approval of pembrolizumab from the Food and Drug Administration. Interesting results have been reported for gene therapies such as those with CG0700 and Adstiladrin, nonreplicating adenovirus able to increase the 'in situ' antitumor activity. However, larger prospective trials with longer follow-up are needed to confirm the initial findings. SUMMARY: In summary, early radical cystectomy remains the standard treatment for BCG unresponsive patients. However, in case of patients unfit for or refusing radical cystectomy, the bladder-sparing options are continuously increasing. Although BCG-reinduction (with or without interferon) and traditional intravesical chemotherapy may represent the past, the present and the future are characterized by device-assisted therapies, systemic immunotherapy, and gene therapy.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc20028042
003      
CZ-PrNML
005      
20210114152847.0
007      
ta
008      
210105s2020 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1097/MOU.0000000000000789 $2 doi
035    __
$a (PubMed)32427633
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Soria, Francesco $u Department of Surgical Sciences, Division of Urology, San Giovanni Battista Hospital, University of Studies of Torino, Turin, Italy.
245    10
$a Bladder sparing landscape for bacillus Calmette-Guérin unresponsive bladder cancer / $c F. Soria, A. Giordano, SF. Shariat, P. Gontero,
520    9_
$a PURPOSE OF REVIEW: The treatment of bacillus Calmette-Guérin (BCG) unresponsive disease remains a challenge for urooncologists. The search for effective conservative treatments is ongoing and several new agents have been recently tested for this purpose. The aim of this manuscript was to review the last developments in this interesting field. RECENT FINDINGS: The advent of systemic immunotherapy in the nonmuscle invasive setting promise to revolutionize the paradigm of treatment of BCG unresponsive disease. The preliminary results of the Keynote-057 trial (3 months complete response of 41% in carcinoma-in-situ patients) have led to the rapid approval of pembrolizumab from the Food and Drug Administration. Interesting results have been reported for gene therapies such as those with CG0700 and Adstiladrin, nonreplicating adenovirus able to increase the 'in situ' antitumor activity. However, larger prospective trials with longer follow-up are needed to confirm the initial findings. SUMMARY: In summary, early radical cystectomy remains the standard treatment for BCG unresponsive patients. However, in case of patients unfit for or refusing radical cystectomy, the bladder-sparing options are continuously increasing. Although BCG-reinduction (with or without interferon) and traditional intravesical chemotherapy may represent the past, the present and the future are characterized by device-assisted therapies, systemic immunotherapy, and gene therapy.
650    _2
$a aplikace intravezikální $7 D000283
650    _2
$a BCG vakcína $x terapeutické užití $7 D001500
650    12
$a genetická terapie $7 D015316
650    _2
$a lidé $7 D006801
650    12
$a imunoterapie $7 D007167
650    _2
$a invazivní růst nádoru $7 D009361
650    _2
$a lokální recidiva nádoru $7 D009364
650    _2
$a léčba šetřící orgány $x metody $7 D059351
650    _2
$a nádory močového měchýře $x terapie $7 D001749
655    _2
$a časopisecké články $7 D016428
655    _2
$a přehledy $7 D016454
700    1_
$a Giordano, Andrea $u Department of Surgical Sciences, Division of Urology, San Giovanni Battista Hospital, University of Studies of Torino, Turin, Italy.
700    1_
$a Shariat, Shahrokh F $u Department of Urology, Medical University of Vienna, Vienna, Austria. Department of Urology, University of Texas Southwestern Medical Center, Dallas, Texas, USA. Department of Urology, Second Faculty of Medicine, Charles University, Prague, Czech Republic. Institute for Urology and Reproductive Health, I.M. Sechenov First Moscow State Medical University, Moscow, Russia. Department of Urology, Weill Cornell Medical College, New York, New York, USA.
700    1_
$a Gontero, Paolo $u Department of Surgical Sciences, Division of Urology, San Giovanni Battista Hospital, University of Studies of Torino, Turin, Italy.
773    0_
$w MED00001296 $t Current opinion in urology $x 1473-6586 $g Roč. 30, č. 4 (2020), s. 542-546
856    41
$u https://pubmed.ncbi.nlm.nih.gov/32427633 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20210105 $b ABA008
991    __
$a 20210114152845 $b ABA008
999    __
$a ok $b bmc $g 1608377 $s 1119222
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2020 $b 30 $c 4 $d 542-546 $e - $i 1473-6586 $m Current opinion in urology $n Curr Opin Urol $x MED00001296
LZP    __
$a Pubmed-20210105

Najít záznam

Citační ukazatele

Pouze přihlášení uživatelé

Možnosti archivace

Nahrávání dat ...